Improvement of erectile function by intracavernous injection of hepatocyte growth factor in a rat model of erectile dysfunction after cavernous nerve injury
Yoo, S1; Park, J1; Son, H1; Kim, SW2; Paick, J-S2; Cho, MC1
1: Seoul National University Boramae Medical Center, Korea, South; 2: Seoul National University, College of Medicine
Objective(s); We investigated whether intracavernous injection of hGF, a potent angiogenic factor, could improve erectile dysfunction in a rat model of erectile dysfunction after cavernous nerve (CN) injury.
Material and Method(s); Sixty 12-week-old male SD rats were divided into five groups as follows: sham control treated with intracavernous injection of saline vehicle (S group), bilateral CN injury treated with intracavernous injection of saline vehicle (I group), bilateral CN injury treated with intracavernous injection of 125 μg hGF (L group), bilateral CN injury treated with intracavernous injection of 250 μg hGF (M group), and bilateral CN injury treated with intracavernous injection of 500 μg hGF (H group). In each group, the hGF or saline vehicle was administrated intracavernously once shortly after CN injury or sham surgery. Erectile function was evaluated by electrostimulation (2.0 V or 4.0 V, 15 Hz, 0.2 ms) and papaverine test at 2 weeks postoperatively.
Result(s); At postoperative 2 weeks, maximum intracavernous pressure (ICP) / mean arterial pressure (MAP) and area under curve (AUC) / MAP in the I group was significantly decreased at all stimulation conditions (2.0 V and 4.0 V) than those in the S group. Although the erectile responses in the L, M, and H groups were significantly improved, ICP / MAP at 2.0 V stimulation in the L, M, and H groups was 48.3%, 41.3%, and 56.1% compared to that in the S group, respectively. In addition, AUC / MAP in the L, M, and H group was 11.6%, 16.1%, and 22.8% compared to that in S group, respectively. Although ICP / MAP and AUC / MAP at 4.0 V stimulation in the L, M, and H groups were significantly improved in the L, M, and H groups compared to those in the I group, partial improvements in ICP / MAP (L group: 41.8%, M group: 44.7%, and H group: 56.6%) and AUC/ MAP (L group: 12.2%, M group: 21.9%, H group: 30.6%) compared to those in the S group was observed, respectively. In terms of papaverine test, ICP in the L, M, and H groups were significantly improved compared to that in the I group, although ICP after papaverine injection was 78.0% in the L group, 58.7% in the M group, and 80.8% in the H group compared with that in the S group.
Conclusion(s); Erectile function was partially improved in a dose dependent manner by immediate intracavernous injection of hGF after CN injury. Further studies are needed to explore whether a combination of hGF with anti-apoptotic agents or anti-fibrotic agents can restore erectile function to control values.
Work supported by industry: yes, by Viromed (no industry support in study design or execution).Go Back